Sertralet 50 mg

What Is Sertralet and What Is It Used For?

Sertralet is a brand name for the antidepressant sertraline, supplied as 50 mg film-coated tablets. It belongs to the class of selective serotonin reuptake inhibitors (SSRIs) and is used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Sertralet works by increasing the amount of serotonin available in the brain, helping to restore chemical balance and improve mood, anxiety and emotional well-being.

Sertralet contains sertraline hydrochloride as its active pharmaceutical ingredient. Sertraline belongs to a group of medications known as selective serotonin reuptake inhibitors (SSRIs). These medications work by selectively blocking the reabsorption (reuptake) of the neurotransmitter serotonin into the presynaptic neuron. By preventing serotonin from being reabsorbed back into nerve cells, sertraline increases the availability of serotonin in the synaptic cleft – the space between nerve cells where chemical signals are transmitted. This enhanced serotonergic activity helps regulate mood, anxiety and emotional responses, and is the mechanism behind the antidepressant and anxiolytic effects observed in clinical practice.

Sertraline, the active ingredient in Sertralet, is one of the most widely prescribed antidepressants globally. It is included on the WHO Model List of Essential Medicines, reflecting its established efficacy, safety and importance in healthcare systems worldwide. Sertraline was first approved by the U.S. Food and Drug Administration (FDA) in 1991 and by the European Medicines Agency (EMA) shortly thereafter. Since then, it has accumulated a robust evidence base spanning more than three decades of clinical use and has been the subject of numerous large, randomised controlled trials and systematic reviews. The landmark Cipriani et al. 2018 network meta-analysis of 21 antidepressants in The Lancet identified sertraline as having one of the best combinations of efficacy and acceptability among all evaluated agents.

Sertralet 50 mg is the starting and most commonly used maintenance strength for sertraline therapy. The 50 mg tablet is typically scored, allowing it to be divided into two 25 mg halves when initiating treatment at a lower dose or when gradually tapering off therapy. For conditions where higher doses are required, patients may be prescribed multiple tablets daily up to a maximum of 200 mg (four tablets per day) under medical supervision.

Approved Indications

Sertralet (sertraline) is approved by regulatory authorities including the EMA, FDA, UK MHRA and other agencies worldwide for the treatment of the following conditions in adults:

• Major depressive disorder (MDD): Treatment of depressive episodes and prevention of recurrent depression in patients who have previously responded to treatment
• Social anxiety disorder (social phobia): Characterised by intense, persistent anxiety and avoidance in social or performance situations
• Post-traumatic stress disorder (PTSD): A condition that can develop after experiencing or witnessing traumatic events
• Panic disorder: With or without agoraphobia, characterised by recurrent unexpected panic attacks
• Obsessive-compulsive disorder (OCD): In adults, and in children and adolescents aged 6–17 years

Depression is a clinical illness characterised by persistent low mood, loss of interest or pleasure in activities (anhedonia), sleep disturbances, fatigue, difficulty concentrating and feelings of worthlessness or hopelessness. It is estimated by the WHO to affect more than 280 million people globally and is a leading cause of disability worldwide. OCD involves distressing intrusive thoughts (obsessions) and repetitive behaviours or mental acts (compulsions) performed to reduce anxiety. Panic disorder is marked by sudden episodes of intense fear accompanied by physical symptoms such as palpitations, sweating, dizziness and a sense of impending doom. PTSD can occur following traumatic experiences and involves symptoms such as flashbacks, nightmares, hypervigilance, avoidance and emotional numbing. Social anxiety disorder involves intense fear and avoidance of social situations due to worries about embarrassment or negative evaluation by others.

Sertralet may also be prescribed off-label for conditions not listed in the approved product information, such as premenstrual dysphoric disorder (PMDD), binge eating disorder, generalised anxiety disorder (GAD) and premature ejaculation. Off-label use should always be based on a careful individual risk-benefit assessment by a qualified prescriber.

What Should You Know Before Taking Sertralet?

Before taking Sertralet, inform your doctor about all medical conditions, current medications, and whether you are pregnant or breastfeeding. Sertralet must never be combined with MAO inhibitors or pimozide because of potentially fatal interactions. Special caution is required for patients with epilepsy, bipolar disorder, liver disease, diabetes, bleeding disorders, glaucoma, or a history of suicidal thoughts.

Before initiating treatment with Sertralet, a thorough medical history and review of current medications should be undertaken. Certain pre-existing conditions and concurrent medications may make sertraline unsuitable, or may require dose adjustment, additional monitoring, or special precautions. The information below summarises the most important contraindications and warnings based on the EMA, FDA, NICE and BNF prescribing information.

Contraindications

You must not take Sertralet in the following situations:

• Allergy to sertraline or any of the excipients contained in the tablets (listed in the composition section below)
• If you are taking or have recently taken monoamine oxidase (MAO) inhibitors such as selegiline, rasagiline, moclobemide, tranylcypromine, phenelzine, the antibiotic linezolid, or intravenous methylene blue. You must wait at least 14 days after stopping an irreversible MAO inhibitor before starting Sertralet, and at least 7 days after stopping Sertralet before starting an MAO inhibitor
• If you are taking pimozide, an antipsychotic medication used for chronic psychotic disorders, because of the risk of QT-interval prolongation and potentially fatal arrhythmias

Warnings and Precautions

Speak to your doctor before taking Sertralet if you have, or have previously had, any of the following conditions:

• Epilepsy or a history of seizures: Sertraline may lower the seizure threshold. Contact your doctor immediately if you experience a seizure while taking Sertralet
• Bipolar disorder or schizophrenia: Sertralet can precipitate a manic or hypomanic episode in susceptible patients. If you experience elevated mood, racing thoughts or reduced need for sleep, contact your doctor immediately
• Suicidal thoughts or self-harm: See the detailed section on suicidal thoughts below
• Serotonin syndrome or neuroleptic malignant syndrome: Rare but serious conditions that can occur when sertraline is combined with other serotonergic medications
• Low blood sodium (hyponatraemia): Can occur during treatment with SSRIs, especially in elderly patients, those taking diuretics, or those with cirrhosis or volume depletion. Symptoms include headache, confusion, weakness and unsteadiness
• Liver disease: Sertraline is extensively metabolised by the liver. A lower dose and less frequent dosing may be required, and caution is advised in severe hepatic impairment
• Diabetes mellitus: Sertraline may alter blood glucose control. Blood sugar should be monitored closely, and insulin or oral antidiabetic medication may need adjustment
• Bleeding disorders or concurrent anticoagulant use: SSRIs including sertraline may increase bleeding risk, particularly gastrointestinal bleeding, when taken with anticoagulants, antiplatelet agents or NSAIDs
• Narrow-angle glaucoma: Sertraline can cause mydriasis (pupil dilation) which may trigger angle-closure glaucoma in predisposed patients
• Cardiac conditions: Including congenital long QT syndrome, prolonged QT interval on ECG, electrolyte disturbances (low potassium or magnesium), or slow heart rate
• Electroconvulsive therapy (ECT): Limited clinical experience with concomitant sertraline and ECT; inform your doctor if you are receiving ECT

Restlessness (Akathisia)

Use of sertraline has been associated with akathisia, a distressing inner restlessness characterised by a compelling need to move, with an inability to sit or stand still. Akathisia typically develops during the first few weeks of treatment or after a dose increase. It is clinically important to recognise akathisia because it may be mistaken for worsening of the underlying condition, and increasing the dose may be harmful. If you develop such symptoms, speak with your doctor – dose reduction or switching to an alternative medication may be required.

Withdrawal (Discontinuation) Reactions

Withdrawal effects when stopping Sertralet are common, particularly if treatment is stopped abruptly or tapered too quickly. The risk depends on the duration of treatment, the dose and how rapidly the dose is reduced. Symptoms typically appear within the first few days after stopping and usually resolve within 2 weeks, although in some patients symptoms may persist for 2–3 months or longer. When discontinuing Sertralet, it is recommended to gradually reduce the dose over several weeks or months under medical supervision. Always discuss with your doctor the best approach to stopping treatment – never discontinue abruptly on your own.

Suicidal Thoughts and Worsening of Depression or Anxiety

If you are depressed or suffer from anxiety, you may sometimes have thoughts of self-harm or suicide. These thoughts may increase when first starting antidepressant treatment, as it takes time for these medications to take effect – typically at least 2 weeks and sometimes longer. During the early treatment period, symptoms may worsen before they improve, and close monitoring is essential.

The risk of suicidal thoughts or self-harm is greater if you:

• Have previously had thoughts of self-harm or suicide
• Are a young adult under 25 years of age. Pooled analyses of clinical trials have shown that young adults with psychiatric conditions treated with antidepressants have an increased risk of suicidal thoughts and behaviours compared with those treated with placebo
• Are experiencing a major life stressor such as bereavement, relationship breakdown, or financial difficulties
• Have a history of substance misuse

Sexual Dysfunction

Medications such as sertraline (SSRIs/SNRIs) can cause symptoms of sexual dysfunction, including decreased libido, delayed or absent ejaculation, erectile difficulties and anorgasmia. In some cases, these symptoms have been reported to persist after discontinuation of treatment, a condition known as post-SSRI sexual dysfunction (PSSD). If you experience sexual side effects, discuss them openly with your doctor – dose adjustment, switching medication, or adding an adjunctive agent may be considered.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant or are planning to have a baby, consult your doctor before taking Sertralet. The safety of sertraline during pregnancy has not been fully established. Decisions about SSRI use during pregnancy require a careful, individualised assessment of the risks of untreated maternal depression or anxiety against the potential risks of medication exposure to the developing fetus. Untreated depression during pregnancy is itself associated with adverse outcomes, including preterm birth, low birth weight and postpartum depression.

Use of SSRI medications during the last three months of pregnancy may increase the risk of persistent pulmonary hypertension of the newborn (PPHN), which causes the baby to breathe faster and appear bluish (cyanotic). Symptoms usually begin within 24 hours of birth. Newborns exposed to SSRIs late in pregnancy may also experience neonatal adaptation symptoms including breathing difficulties, feeding problems, irritability, tremor, muscle stiffness or limpness, hypoglycaemia and, rarely, seizures. If your newborn develops any of these symptoms, contact your doctor or midwife immediately.

Sertraline passes into breast milk in small amounts. In general, published data suggest that sertraline is one of the preferred SSRIs for breastfeeding mothers, as relative infant doses are low and adverse effects in breastfed infants are rare. However, Sertralet should only be given to breastfeeding women if the benefit clearly outweighs the potential risks to the infant, and the infant should be monitored for sedation, feeding difficulties or poor weight gain.

Children and Adolescents

Sertralet should generally not be used in children and adolescents under 18 years of age, except for the treatment of OCD in patients aged 6–17 years. The risk of side effects such as suicidal behaviour, self-harm thoughts and hostility (aggression, defiance, anger) is greater in patients under 18. A long-term safety study of more than 900 children aged 6–16 years followed over a 3-year period showed that children treated with sertraline generally developed normally, apart from a small weight gain in those treated with higher doses.

Driving and Operating Machinery

Psychotropic medications such as sertraline may affect your ability to drive or operate machinery, particularly in the early weeks of treatment or after a dose change. Side effects such as drowsiness, dizziness and blurred vision can impair alertness and reaction time. You should not drive or operate machinery until you know how Sertralet affects you. Discuss any concerns with your doctor.

How Does Sertralet Interact with Other Drugs?

Sertralet has significant interactions with several medications. It must never be combined with MAO inhibitors or pimozide due to the risk of life-threatening reactions. Many other medications – including blood thinners, lithium, tramadol, triptans, St. John's Wort and NSAIDs – require careful monitoring when taken with Sertralet. Always inform your doctor of all prescription, over-the-counter and herbal medications you are taking.

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications, including herbal products and over-the-counter medicines. Some medications can affect how Sertralet works (pharmacokinetic interactions), and Sertralet can affect how other medications work. The most clinically important interactions involve other serotonergic agents, drugs affecting the CYP2D6, CYP2C19 and CYP3A4 enzyme systems, and drugs with narrow therapeutic indices.

Major Interactions (Do Not Combine)

Moderate Interactions (Use with Caution)

Food and Alcohol Interactions

Sertralet tablets may be taken with or without food. However, the following considerations apply:

• Alcohol: Should be avoided during treatment. Alcohol affects the central nervous system and can intensify side effects such as drowsiness, dizziness and impaired judgment, and may counteract the therapeutic effects of the medication. Alcohol also worsens depressive and anxiety symptoms
• Grapefruit juice: Should be avoided while taking Sertralet, as it can increase sertraline plasma levels by inhibiting the CYP3A4 enzyme involved in sertraline metabolism
• Caffeine: No direct pharmacokinetic interaction, but excessive caffeine intake may worsen anxiety, insomnia and tremor – side effects that overlap with sertraline's own profile

What Is the Correct Dosage of Sertralet?

The usual effective dose of Sertralet (sertraline) for depression and OCD in adults is 50 mg once daily, which can be increased up to a maximum of 200 mg daily. For panic disorder, PTSD and social anxiety disorder, treatment usually starts at 25 mg daily (half a Sertralet tablet) and is increased to 50 mg after one week. Sertralet should be taken once daily, either in the morning or the evening, with or without food.

Dosing should always be individualised and titrated to the lowest effective dose by a qualified prescriber. Dose adjustments should generally be made at intervals of at least one week to allow time to assess response and tolerability. The 50 mg Sertralet tablet is scored to facilitate accurate dosing, including the 25 mg starting dose used for panic and anxiety indications.

Adults

Doses may be increased in increments of 50 mg at intervals of at least one week. Your doctor will determine the appropriate dose and duration of treatment based on your condition, clinical response and tolerability. For major depressive disorder, treatment should usually be continued for at least 6–9 months after symptom remission to minimise the risk of relapse. For recurrent depression, long-term maintenance therapy may be recommended. For OCD and anxiety disorders, treatment courses are typically longer, often 12 months or more. It may take several weeks before symptoms begin to improve – you should not stop treatment early based on the absence of immediate effect.

Children and Adolescents (OCD Only)

Sertralet is only approved for use in children and adolescents aged 6–17 years for the treatment of obsessive-compulsive disorder:

• Children aged 6–12 years: Starting dose of 25 mg once daily (half of a scored 50 mg Sertralet tablet), which may be increased to 50 mg daily after one week. Maximum dose: 200 mg daily
• Adolescents aged 13–17 years: Starting dose of 50 mg once daily. Maximum dose: 200 mg daily

In paediatric patients, dose increases should be made cautiously and at intervals of at least one week. Children taking Sertralet should be closely monitored for suicidal thoughts, behavioural changes and growth.

Elderly and Patients with Liver or Kidney Problems

Elderly patients may be more susceptible to certain side effects, particularly low blood sodium (hyponatraemia), bleeding and falls. Although no specific dose adjustment is routinely required in older adults, initiation at the lower end of the dosage range and careful titration are recommended. In patients with hepatic impairment, sertraline clearance is reduced, and a lower dose or less frequent dosing should be used. In patients with renal impairment, no dose adjustment is generally required because sertraline is primarily cleared by hepatic metabolism, but caution is advised and dosing should always be discussed with the prescriber.

How to Take Sertralet

Take Sertralet exactly as your doctor has instructed. Key practical points:

• Swallow the tablet whole with a glass of water. The scored 50 mg tablet can be divided along the score line to provide a 25 mg dose
• Sertralet can be taken with or without food. Taking it with food may reduce the mild nausea that some patients experience in the early weeks
• Take the medication at the same time each day – morning dosing is often preferred if insomnia is a problem, whereas evening dosing may suit patients who experience daytime drowsiness
• Do not stop taking Sertralet without speaking to your doctor first, even if you feel better

Missed Dose

If you forget to take a dose of Sertralet, do not take a double dose to make up for the missed one. Simply skip the missed dose and take your next dose at the regular scheduled time. Taking a double dose increases the risk of side effects without providing additional therapeutic benefit. If you frequently forget doses, consider setting a daily alarm or using a pill organiser.

Overdose

If you or someone else takes too much Sertralet, contact your doctor, a poisons information centre or emergency department immediately. Always bring the medication packaging with you. Symptoms of sertraline overdose may include drowsiness, nausea and vomiting, tachycardia (rapid heartbeat), tremor, agitation, dizziness, hyperreflexia, and in more severe cases serotonin syndrome, seizures, QT prolongation or loss of consciousness. Serious outcomes are uncommon with sertraline alone, but risk is significantly increased when taken together with other serotonergic agents, alcohol or illicit drugs. Treatment of overdose is supportive and symptomatic; there is no specific antidote.

What Are the Side Effects of Sertralet?

Like all medicines, Sertralet can cause side effects, although not everyone experiences them. The most common side effect is nausea, which usually improves within the first 1–2 weeks of treatment. Most side effects are dose-dependent and tend to diminish with continued use. Serious side effects such as serotonin syndrome, severe skin reactions, hyponatraemia and suicidal thoughts require immediate medical attention.

The side effect profile of Sertralet reflects that of sertraline more broadly and has been extensively characterised over more than three decades of clinical use. Most adverse effects are mild to moderate, dose-dependent and tend to resolve within the first few weeks as the body adapts. The side effects listed below are grouped by frequency of occurrence, based on pooled data from clinical trials and post-marketing surveillance as reported in the EMA SmPC and FDA prescribing information.

Side Effects in Children and Adolescents

In clinical studies with children and adolescents taking sertraline, the pattern of side effects was generally similar to those observed in adults. The most common side effects in paediatric patients were headache, insomnia, diarrhoea and nausea. Additional reported adverse effects that may be more prominent in paediatric populations include weight loss, agitation, hyperkinesia (restlessness) and aggression. Close clinical monitoring is essential, particularly during the first few months of treatment and after any dose change.

Withdrawal / Discontinuation Symptoms

If you stop taking Sertralet suddenly, you may experience withdrawal symptoms (also called discontinuation syndrome) including dizziness, sensory disturbances such as electric-shock sensations or tingling (paraesthesia), sleep disturbances and vivid dreams, agitation or anxiety, headache, nausea, vomiting, tremor, and flu-like symptoms. These symptoms are usually mild to moderate but can be severe in some individuals. The risk can be minimised by gradually tapering the dose over at least 2–4 weeks under your doctor's supervision.

Reporting of Side Effects

If you experience any side effects, talk to your doctor or pharmacist. You can also help by reporting side effects directly to your national pharmacovigilance authority – for example the FDA MedWatch programme in the United States, the Yellow Card Scheme in the United Kingdom, or the relevant EMA national competent authority in Europe. Reporting side effects helps provide further information on the safety of this medicine.

How Should You Store Sertralet?

Store Sertralet at room temperature below 30°C in the original packaging, out of the reach and sight of children. Do not use the medication after the expiry date printed on the packaging. Do not dispose of unused medication via wastewater or household waste – return it to your pharmacy for safe disposal.

Keep Sertralet out of the reach and sight of children. Store the tablets in the original blister pack or bottle to protect them from moisture and light. No special temperature storage conditions are generally required for sertraline film-coated tablets, but they should not be stored above 30°C. Avoid storing the medication in bathrooms or other humid environments, as humidity can affect tablet stability.

Do not use Sertralet after the expiry date printed on the carton and blister pack after "EXP." The expiry date refers to the last day of the stated month. Using expired medication is not recommended, as the active ingredient may have degraded and the medication may no longer be fully effective.

Do not throw away medications via wastewater (such as down the sink or toilet) or household waste. Unused or expired Sertralet should be returned to your pharmacy for safe disposal. Many countries operate pharmaceutical take-back schemes. These measures help protect the environment from pharmaceutical contamination of water and soil.

What Does Sertralet Contain?

Each Sertralet 50 mg film-coated tablet contains sertraline hydrochloride equivalent to 50 mg of sertraline as the active ingredient. Typical inactive ingredients (excipients) include hydroxypropyl cellulose, microcrystalline cellulose, sodium starch glycolate, calcium hydrogen phosphate dihydrate and magnesium stearate in the tablet core, with a film coating of titanium dioxide (E171), hypromellose, macrogol and polysorbate.

Active Ingredient

The active substance is sertraline hydrochloride. Each Sertralet film-coated tablet contains sertraline hydrochloride equivalent to 50 mg of sertraline (the active base). Sertraline hydrochloride is a white to off-white crystalline powder that is slightly soluble in water, giving it the pharmacokinetic properties required for reliable once-daily oral dosing.

Inactive Ingredients (Excipients)

The typical excipients in a sertraline 50 mg film-coated tablet such as Sertralet are:

Tablet core: hydroxypropyl cellulose, microcrystalline cellulose, sodium starch glycolate Type A, calcium hydrogen phosphate dihydrate and magnesium stearate.

Film coating: titanium dioxide (E171), hypromellose, macrogol 400 and polysorbate 80.

The tablets are white to off-white, film-coated, capsule-shaped or oval biconvex tablets. The 50 mg Sertralet tablet carries a score line and can be divided into two equal 25 mg doses, which is useful when initiating therapy at a lower starting dose or tapering before discontinuation. The medication contains less than 1 mmol (23 mg) of sodium per tablet, so it is considered essentially "sodium-free."

If you have known allergies or intolerances, review the excipient list carefully. Patients with rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should check the specific product leaflet, as excipient composition may vary between manufacturers and generic versions. Always consult the patient information leaflet supplied with your specific pack of Sertralet for the definitive list of ingredients.

Frequently Asked Questions About Sertralet